Officer at CG Oncology (CGON) awarded 45,266 stock options

Rhea-AI Filing Summary

CG Oncology, Inc. reported that officer Joshua F. Patterson received an employee stock option grant covering 45,266 shares of common stock. The option has an exercise price of $67.68 per share and expires on April 14, 2036.

According to the terms, 1/48th of the option vests each month after the vesting commencement date of April 15, 2026, as long as Patterson remains in continuous service with the company. This is a compensation-related equity award rather than an open-market stock purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Patterson Joshua F.

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	45,266	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 45,266 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 45,266 options Exercise price: $67.68 per share Shares underlying option: 45,266 shares +3 more

6 metrics

Option grant size 45,266 options Employee stock option grant to Joshua F. Patterson

Exercise price $67.68 per share Strike price for employee stock option

Shares underlying option 45,266 shares Common stock underlying the derivative grant

Post-transaction derivative holdings 45,266 options Total options held after this grant

Option expiration date April 14, 2036 Final date to exercise granted options

Vesting commencement date April 15, 2026 Date monthly vesting of 1/48th begins

Key Terms

Employee Stock Option, exercise price, vesting, expiration date, +1 more

5 terms

Employee Stock Option financial

"Employee Stock Option (Right to Buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

exercise price financial

"conversion or exercise price of 67.6800 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/48th of the shares subject to the option vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration date of 2036-04-14"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

derivative financial

"transaction_type set to derivative for this option grant"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patterson Joshua F.

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$67.68	04/15/2026		A		45,266		(1)	04/14/2036	Common Stock	45,266	$0	45,266	D

Explanation of Responses:

1. 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Remarks:

General Counsel and Chief Compliance Officer

	/s/ Joshua F. Patterson	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CG Oncology (CGON) report for Joshua F. Patterson?

CG Oncology reported a grant of employee stock options to officer Joshua F. Patterson. He received options for 45,266 shares of common stock as compensation, documented as an acquisition rather than an open-market purchase or sale.

What is the exercise price of Joshua F. Patterson’s CG Oncology (CGON) stock options?

The granted employee stock options have an exercise price of $67.68 per share. This means Patterson can later buy CG Oncology common stock at $67.68 per share once the options vest and before they expire, subject to his continued service.

How do the CG Oncology (CGON) stock options granted to Joshua F. Patterson vest?

The options vest gradually over time. One forty-eighth (1/48th) of the shares subject to the option vest each month after April 15, 2026, provided Patterson remains in continuous service with CG Oncology through each monthly vesting date.

When do Joshua F. Patterson’s CG Oncology (CGON) stock options expire?

The employee stock options granted to Patterson expire on April 14, 2036. He must exercise any vested options before that expiration date; unexercised options after that date would lapse and become worthless under the grant’s stated terms.

Does the CG Oncology (CGON) Form 4 show a stock sale or purchase by Joshua F. Patterson?

The Form 4 shows an acquisition of derivative securities through an employee stock option grant, not an open-market trade. The transaction code is “A,” indicating a grant or award, with no reported buying or selling of common shares in the market.